Hikma Pharmaceuticals’ (HIK) “Buy” Rating Reiterated at Jefferies Financial Group

Hikma Pharmaceuticals (LON:HIK)‘s stock had its “buy” rating reiterated by research analysts at Jefferies Financial Group in a research note issued to investors on Thursday, Digital Look reports. They presently have a GBX 2,025 price objective on the stock. Jefferies Financial Group‘s price target would indicate a potential upside of 21.77% from the company’s current price.

Several other analysts have also commented on HIK. Berenberg Bank lifted their price objective on shares of Hikma Pharmaceuticals from GBX 1,800 to GBX 2,100 and gave the stock a “buy” rating in a research report on Tuesday, August 11th. Citigroup boosted their target price on Hikma Pharmaceuticals from GBX 1,700 to GBX 1,870 and gave the company a “buy” rating in a research note on Wednesday, August 12th. Finally, Deutsche Bank Aktiengesellschaft restated a “buy” rating and issued a GBX 1,950 target price on shares of Hikma Pharmaceuticals in a research note on Friday, August 7th. Six investment analysts have rated the stock with a Buy rating. According to MarketBeat.com, Hikma Pharmaceuticals has a consensus rating of “Buy” and a consensus target price of GBX 2,085.83.

Hikma Pharmaceuticals Stock Performance

Shares of HIK stock opened at GBX 1,663 on Thursday. The company has a debt-to-equity ratio of 77.57, a current ratio of 1.98 and a quick ratio of 1.27. The company has a market cap of £3.44 billion, a P/E ratio of 9.45, a P/E/G ratio of 2.38 and a beta of 0.65. Hikma Pharmaceuticals has a one year low of GBX 1,187 and a one year high of GBX 1,762. The firm has a 50-day moving average of GBX 1,626.31 and a 200-day moving average of GBX 1,507.66.

Insider Activity at Hikma Pharmaceuticals

In related news, insider Tobias Hestler acquired 7,500 shares of the firm’s stock in a transaction that occurred on Monday, August 10th. The shares were bought at an average cost of GBX 1,648 per share, for a total transaction of £123,600. Insiders own 22.26% of the company’s stock.

About Hikma Pharmaceuticals

At Hikma we help put better health within reach, every day. By creating high-quality medicines and making them accessible to the people who need them, we help to shape a healthier world that enriches all our communities. We help deliver this by living our culture, delivering our strategy, and acting responsibly. We are a trusted, reliable partner and dependable source of over 820+ (as of Feb 2026) high-quality generic, specialty and branded pharmaceutical products that hospitals, physicians and pharmacists need to treat their patients across North America, MENA and Europe.